Lowest Price Guaranteed From USD 4,899
The cell reprogramming market is estimated to be worth $1.16 billion in 2020 and is expected to grow at compounded annual growth rate (CAGR) of 8% during the forecast period. Over the years, advances in stem cell biology and regenerative medicine have enabled the discovery and development of a number of stem cell-based therapies. In fact, many believe that such interventions possess the potential to address several unmet needs related to the treatment of a wide range of diseases. Stem cell-based treatments are known for their ability to replace damaged cells and tissues, thereby, effectively reversing the adverse physiological effects they cause. However, challenges, such as scarcity of healthy stem cell donors, adverse immunological reactions upon treatment (owing to donor-recipient haplotype mismatches), and a number of ethical concerns related to the use of stem cells, are impeding progress in this field.
The discovery of induced pluripotent stem cells (iPSCs) by Shinya Yamanaka’s team in 2006 revolutionized stem cell research. Through his Nobel prize winning research, Yamanaka was able to reprogram mature somatic cells into a stem-like (pluripotent) state. This finding not only established the means to synthesize stem cells (thereby, offering a virtually endless supply of research material), but also provided the means to alleviate the social stigma surrounding stem cell research. Presently, cellular reprogramming is perceived as a powerful and versatile tool, with numerous applications in fundamental research and medicine. It is worth mentioning that, today, many experts believe that stem cell therapies may be a possible solution to the COVID-19 pandemic. In fact, there are speculations, based on some evidence, that infected patients treated with stem cells may be more likely to successfully combat the symptoms of the disease. Research has also demonstrated that mesenchymal stem cells have the potential to be effectively used to treat SARS-CoV-2 induced pneumonia. Numerous partnerships have been inked amongst stakeholders in cell reprogramming market, indicative to future growth of the market. Interestingly, start-ups / university spin-offs have been the flagbearers in this upcoming field of therapeutics and are also expected to sustain the research momentum, over the coming years.
Examples of key companies engaged in cell reprogramming market (which have also been profiled in this market report; the complete list of companies is available in the full report) include Allele Biotechnology, ALSTEM, Applied Biological Materials, Axol Bioscience, Creative Bioarray, DefiniGEN, FUJIFILM Cellular Dynamics International, Lonza, Mogrify, REPROCELL, Stemnovate and Thermo Fisher Scientific. This market report includes an easily searchable excel database of all the companies providing cell reprogramming services and products, worldwide.
Several recent developments have taken place in the field of cell reprogramming market. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.
The ‘Cell Reprogramming Market, 2020-2030’ market report features an extensive study of the current market landscape, market size, market share, market growth, market trends, market value, market forecast, market outlook, statistics and future opportunities of the cell reprogramming market. It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in cell reprogramming market.
In addition to other elements, the market research report includes:
The key objective of cell reprogramming market report is to provide a detailed market analysis in order to estimate the existing market size, market share, market growth, market trends, market value, market forecast, market outlook, statistics and future opportunity for cell reprogramming market during the forecast period. Based on multiple parameters, such as growth of the overall iPSC market, reprogramming cost and annual number of projects for stem cell therapies, we have provided an informed estimate of the likely evolution of the market in the short to mid-term and mid to long term, for the forecast period, 2020-2030. The market report also features the likely distribution of the current and forecasted opportunity within cell reprogramming services and products market across [A] type of technology offered (sendai virus-based reprogramming, mRNA reprogramming, episomal reprogramming and other technologies), [B] Source cells for iPSC generation (fibroblasts, blood mononuclear cells, unspecified somatic cells and other cells), [C] type of application (research and therapeutic), and [D] key geographical regions (North America, Europe and Asia- Pacific and rest of the world). To account for the uncertainties associated with the development of reprogrammed cells and to add robustness to our model, we have provided three market forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.
The opinions and insights presented in the market report were influenced by discussions held with senior stakeholders in the industry. The market research report features detailed transcripts of interviews held with the following industry stakeholders:
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this market research report are in USD, unless otherwise specified.